RxDoctor Payments Data

Aaron Lech

Optometrist · Roseville, CANPI 1053365254

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $68,125 of the $99,842 with a category attached, or 68.2%. Carl Zeiss Meditec, Inc. accounts for 93.3% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2019 at $37,607 and has fallen 91.1% since, to $3,365 in 2025. Among optometrist clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$99,842in general payments, 2019–2025

Across 141 payments — averaging $708.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec, Inc.$93K
  • AbbVie$3K
  • Novo Nordisk AS$2K
  • Carl Zeiss Meditec USA, Inc.$1K
  • Tarsus Pharmaceuticals, Inc.$521
  • Johnson & Johnson Vision Care, Inc.$227
  • plus $554 from 11 others
$13,790in research payments, 2019–2025

Across 4 payments — averaging $3447.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Alcon Research LLC$14K

What the payments were for

  • Consulting fees$68,12568%
  • Speaking & faculty fees$19,10019%
  • Travel & lodging$7,6958%
  • Food & beverage$4,9225%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$99,842 in reported general payments places this provider in the 95th percentile of 6,778 optometrist providers in California.

See all optometrist providers in California

Medicare billing

Part B allowed, 2024
$96,055
Medicare patients
220
Services billed
1,128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cyclosporine11$2,157
Loteprednol Etabonate24$2,107
Latanoprost79$590
Timolol Maleate21$147

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$116$2,10724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,778 optometrist providers in California.

Other optometrist in Roseville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →